USD
+$0.00
(+0.00%
)At Close (As of Nov 4, 2025)
$2.63B
Market Cap
5.78
P/E Ratio
2.65
EPS
$19.50
52 Week High
$11.51
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $281M |
| Total Revenue | $630M |
| Cost Of Revenue | $349M |
| Costof Goods And Services Sold | $349M |
| Operating Income | -$44M |
| Selling General And Administrative | $64M |
| Research And Development | $213M |
| Operating Expenses | $322M |
| Investment Income Net | - |
| Net Interest Income | $37M |
| Interest Income | $40M |
| Interest Expense | $2.9M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $12M |
| Income Before Tax | $45M |
| Income Tax Expense | $7.2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $38M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $1.8M |
| Ebitda | $14M |
| Net Income | $38M |
| Field | Value (USD) |
|---|---|
| Total Assets | $1.3B |
| Total Current Assets | $1.1B |
| Cash And Cash Equivalents At Carrying Value | $154M |
| Cash And Short Term Investments | $154M |
| Inventory | $50M |
| Current Net Receivables | $168M |
| Total Non Current Assets | $208M |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | $3M |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | $682M |
| Other Current Assets | $12M |
| Other Non Current Assets | - |
| Total Liabilities | $502M |
| Total Current Liabilities | $377M |
| Current Accounts Payable | $43M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $26M |
| Total Non Current Liabilities | $126M |
| Capital Lease Obligations | $7M |
| Long Term Debt | $59M |
| Current Long Term Debt | $23M |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $90M |
| Other Current Liabilities | $306M |
| Other Non Current Liabilities | $11M |
| Total Shareholder Equity | $760M |
| Treasury Stock | - |
| Retained Earnings | -$833M |
| Common Stock | $87M |
| Common Stock Shares Outstanding | $175M |
| Field | Value (USD) |
|---|---|
| Operating Cashflow | $497K |
| Payments For Operating Activities | - |
| Proceeds From Operating Activities | - |
| Change In Operating Liabilities | - |
| Change In Operating Assets | - |
| Depreciation Depletion And Amortization | $12M |
| Capital Expenditures | $18M |
| Change In Receivables | - |
| Change In Inventory | -$772K |
| Profit Loss | - |
| Cashflow From Investment | -$96M |
| Cashflow From Financing | -$31M |
| Proceeds From Repayments Of Short Term Debt | - |
| Payments For Repurchase Of Common Stock | - |
| Payments For Repurchase Of Equity | - |
| Payments For Repurchase Of Preferred Stock | - |
| Dividend Payout | - |
| Dividend Payout Common Stock | - |
| Dividend Payout Preferred Stock | - |
| Proceeds From Issuance Of Common Stock | - |
| Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
| Proceeds From Issuance Of Preferred Stock | - |
| Proceeds From Repurchase Of Equity | -$36M |
| Proceeds From Sale Of Treasury Stock | - |
| Change In Cash And Cash Equivalents | - |
| Change In Exchange Rate | - |
| Net Income | $38M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $281M |
| Total Revenue | $630M |
| Cost Of Revenue | $349M |
| Costof Goods And Services Sold | $349M |
| Operating Income | -$44M |
| Selling General And Administrative | $64M |
| Research And Development | $213M |
| Operating Expenses | $322M |
| Investment Income Net | - |
| Net Interest Income | $37M |
| Interest Income | $40M |
| Interest Expense | $2.9M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $12M |
| Income Before Tax | $45M |
| Income Tax Expense | $7.2M |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | $38M |
| Comprehensive Income Net Of Tax | - |
| Ebit | $1.8M |
| Ebitda | $14M |
| Net Income | $38M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
HUTCHMED (China) Limited is a prominent biopharmaceutical firm headquartered in Central, Hong Kong, specializing in the discovery, development, and commercialization of innovative targeted therapies and immunotherapies for oncology and immune-related conditions in global markets. The company boasts a strong pipeline and leverages advanced research capabilities alongside extensive clinical development expertise to meet significant unmet medical needs in cancer care. With strategic partnerships and a commitment to delivering cutting-edge therapies, HUTCHMED is well-positioned to capitalize on the increasing global demand for advanced cancer treatments, thereby enhancing potential growth and value for its investors.